Sight Sciences is a medical device company dedicated to the development of technology-driven solutions that address the underlying physiology of ophthalmic disease. The company operates two business lines: surgical and non-surgical devices. Its surgical product portfolio consists of the TRAB360 and VISCO360 surgical devices. Its non-surgical product portfolio consists of technologies in the advanced stages of development for evaporative dry eye.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/15/16 | $7,000,000 | Series B |
Allegro Investment Fund Hicks Equity Partners Scientific Health Development | undisclosed |
| 10/09/17 | $10,000,000 | Series C |
Allegro Investment Fund Hicks Equity Partners Scientific Health Development | undisclosed |
| 03/18/20 | $30,000,000 | Series E |
D1 Capital Partners | undisclosed |
